eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
4/2019
vol. 23
 
Share:
Share:
more
 
 
abstract:
Original paper

Cancer immunotherapy experience in the Integral Oncology Centre “Diana Laura Riojas de Colosio”, Médica Sur Hospital

Ricardo Fernández-Ferreira
,
Daniel Motola-Kuba
,
Ileana Mackinney-Novelo
,
José Manuel Ruiz-Morales
,
María Eugenia Torres-Pérez

Contemp Oncol (Pozn) 2019; 23 (4): 239-246
Online publish date: 2019/12/30
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
The use of immunotherapy in Mexico has been used since 2012 with ipilimumab and since 2015 with nivolumab and pembrolizumab, so it is a matter of necessity to know the experience of these drugs.

Material and methods
An observational, descriptive, cross-sectional, and retrospective study was performed in Médica Sur Hospital, where with dossiers from 2012 to June 2018 patients with metastatic cancer who received immunotherapy with ipilimumab, nivolumab, and pembrolizumab for six months were evaluated, searching as principal outcomes the adverse effects of those drugs and as secondary outcomes the response to treatment.

Results
Seventy subjects fulfilled the inclusion criteria for the study, and 42 (60%) were women with an average age of 60.73 ±13.64 years (16–82 years). The pathologies that received immunotherapy were the following: melanoma and lung cancer. The most frequent clinical and laboratory adverse effects were as follows: fatigue – 32 (45.71%), asthaenia – 30 (42%), nausea – 8 (11.4%), diarrhoea – 8 (11.4%), and rash – 7 (10%). The worst adverse effects were respiratory and endocrinological: pneumonitis – 10 (14.28%), hypothyroidism – 4 (5.71%), hyperglycaemia – 1 (1.4%), and hypophysitis – 2 (2.9%). With respect to treatment response: complete response – 8 (11.4%), partial response – 11 (15.71%), stable disease – 33 (47.14%), and disease progression – 19 (27.14%).

Conclusions
The most common adverse effects did not condition the suspension of treatment or increase in intra-hospital stay, but there were some adverse effects that actually had an impact on evolution, hospital stay, and mortality.

keywords:

cancer, immunotherapy, ipilimumab, nivolumab, pembrolizumab

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe